RBC Capital Reiterates Outperform on HOOKIPA Pharma, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on HOOKIPA Pharma (NASDAQ:HOOK) and maintained a $5 price target.
May 21, 2024 | 5:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on HOOKIPA Pharma and maintained a $5 price target, indicating continued confidence in the company's performance.
The reiteration of an Outperform rating and the maintenance of a $5 price target by RBC Capital suggests that the analyst has a positive outlook on HOOKIPA Pharma's future performance. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100